

Nicholas Blagden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/173900/publications.pdf>

Version: 2024-02-01

49
papers

4,203
citations

201385

27
h-index

197535

49
g-index

52
all docs

52
docs citations

52
times ranked

4066
citing authors

#	ARTICLE	IF	CITATIONS
1	Rational Development of a Carrier-Free Dry Powder Inhalation Formulation for Respiratory Viral Infections via Quality by Design: A Drug-Drug Cocrystal of Favipiravir and Theophylline. <i>Pharmaceutics</i> , 2022, 14, 300.	2.0	16
2	Chameleon Behavior of a New Salt of 3-(Aminocarbonyl) Pyridinium Malonate and Implications for Polymorphism on the Salt/Cocrystal Continuum. <i>Crystal Growth and Design</i> , 2022, 22, 1665-1679.	1.4	9
3	First Steps for the Direct Purification of <sc>l</sc>-Leu-<sc>l</sc>-Leu Dipeptide through Co-Crystallization. <i>Crystal Growth and Design</i> , 2018, 18, 1062-1069.	1.4	5
4	Serendipitous isolation of a disappearing conformational polymorph of succinic acid challenges computational polymorph prediction. <i>CrystEngComm</i> , 2018, 20, 3971-3977.	1.3	19
5	The Impact of Trifluoroacetic Acid on Peptide Cocrystallization: Multicomponent Crystals of <sc>l</sc>-Leu-<sc>l</sc>-Leu Dipeptides. <i>Crystal Growth and Design</i> , 2018, 18, 4682-4690.	1.4	2
6	First Comparative Study of the Three Polymorphs of Bis(isonicotinamide) Citric Acid Cocrystals and the Concomitant Salt 4-Carbamoylpyridinium Citrate Isonicotinamide. <i>Crystal Growth and Design</i> , 2018, 18, 4150-4159.	1.4	15
7	Impact of Mixed Solvent on Co-Crystal Solubility, Ternary Phase Diagram, and Crystallization Scale Up. <i>Crystal Growth and Design</i> , 2016, 16, 1817-1823.	1.4	8
8	Stoichiometric Control of Co-Crystal Formation by Solvent Free Continuous Co-Crystallization (SFCC). <i>Crystal Growth and Design</i> , 2015, 15, 5648-5651.	1.4	25
9	Pharmaceutical co-crystals “are we there yet?”. <i>CrystEngComm</i> , 2014, 16, 5753-5761.	1.3	85
10	Evaluation of a Nanodispersion Formulation Prepared through Microfluidic Reactors for Pulmonary Delivery of Budesonide Using Nebulizers. <i>Iranian Journal of Pharmaceutical Research</i> , 2014, 13, 785-95.	0.3	4
11	Tuning Proton Disorder in 3,5-Dinitrobenzoic Acid Dimers: the Effect of Local Environment. <i>Crystal Growth and Design</i> , 2013, 13, 497-509.	1.4	30
12	Creation of Ternary Multicomponent Crystals by Exploitation of Charge-Transfer Interactions. <i>Chemistry - A European Journal</i> , 2013, 19, 10663-10671.	1.7	33
13	Development of a novel liquid crystal based cell traction force transducer system. <i>Biosensors and Bioelectronics</i> , 2013, 39, 14-20.	5.3	23
14	Solubility of salbutamol and salbutamol sulphate in ethanol+water mixtures at 25°C. <i>Journal of Molecular Liquids</i> , 2012, 173, 62-65.	2.3	18
15	Influence of Solvent on the Morphology and Subsequent Comminution of Ibuprofen Crystals by Air Jet Milling. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 1108-1119.	1.6	30
16	Rheological characterization and in-situ investigation of the time-dependent cholesteric based lyotropic liquid crystals. <i>Materials Science and Engineering C</i> , 2011, 31, 1389-1397.	3.8	12
17	Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling. <i>Journal of Controlled Release</i> , 2011, 149, 175-181.	4.8	209
18	Spontaneous crystal growth of co-crystals: the contribution of particle size reduction and convection mixing of the co-formers. <i>CrystEngComm</i> , 2011, 13, 1141-1152.	1.3	39

#	ARTICLE	IF	CITATIONS
19	Solubility of Budesonide, Hydrocortisone, and Prednisolone in Ethanol + Water Mixtures at 298.2 K. <i>Journal of Chemical & Engineering Data</i> , 2010, 55, 578-582.	1.0	43
20	Tuning Proton Behavior in a Ternary Molecular Complex. <i>Crystal Growth and Design</i> , 2010, 10, 2770-2774.	1.4	34
21	Artificial neural networks modelling the prednisolone nanoprecipitation in microfluidic reactors. <i>European Journal of Pharmaceutical Sciences</i> , 2009, 37, 514-522.	1.9	51
22	Preparation of hydrocortisone nanosuspension through a bottom-up nanoprecipitation technique using microfluidic reactors. <i>International Journal of Pharmaceutics</i> , 2009, 375, 107-113.	2.6	190
23	Controlling the Formation of Benzoic Acid: Isonicotinamide Molecular Complexes. <i>Crystal Growth and Design</i> , 2009, 9, 47-56.	1.4	85
24	Formation of a hybrid coordination-molecular complex. <i>CrystEngComm</i> , 2009, 11, 1793.	1.3	11
25	Current directions in co-crystal growth. <i>New Journal of Chemistry</i> , 2008, 32, 1659.	1.4	139
26	Applying Hot-Stage Microscopy to Co-Crystal Screening: A Study of Nicotinamide with Seven Active Pharmaceutical Ingredients. <i>Crystal Growth and Design</i> , 2008, 8, 1697-1712.	1.4	293
27	Growth of an Organic Co-Crystal upon a Component Subphase. <i>Crystal Growth and Design</i> , 2008, 8, 363-368.	1.4	18
28	Application of Crystallization Inhibitors to Chiral Separations. 1. Design of Additives to Discriminate between the Racemic Compound and the Pure Enantiomer of Mandelic Acid. <i>Crystal Growth and Design</i> , 2007, 7, 218-224.	1.4	16
29	Designing Hydrogen Bonds with Temperature-Dependent Proton Disorder: The Effect of Crystal Environment. <i>Crystal Growth and Design</i> , 2007, 7, 531-534.	1.4	34
30	Solvent Influences on Metastable Polymorph Lifetimes: Real-Time Interconversions Using Energy Dispersive X-Ray Diffractometry**We dedicate this paper to Professor David Grant. Not only a talented scientist, he was a man who gave freely of his time and ideas to support and encourage others, including ourselves.. <i>Journal of Pharmaceutical Sciences</i> , 2007, 96, 1069-1078.	1.6	24
31	Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. <i>Advanced Drug Delivery Reviews</i> , 2007, 59, 617-630.	6.6	1,103
32	Polymorphism in Benzamide. <i>Angewandte Chemie - International Edition</i> , 2005, 44, 7032-7035.	7.2	71
33	Ordered Aggregation of Benzamide Crystals Induced Using a β -Motif Capper Additive. <i>Crystal Growth and Design</i> , 2005, 5, 467-471.	1.4	14
34	Woehler and Liebig Revisited: A Small Molecule Reveals Its SecretsThe Crystal Structure of the Unstable Polymorph of Benzamide Solved after 173 Years. <i>Crystal Growth and Design</i> , 2005, 5, 2218-2224.	1.4	40
35	Crystal Growth Mechanisms. , 2004, , 364-370.		0
36	A Whole Output Strategy for Polymorph Screening: Combining Crystal Structure Prediction, Graph Set Analysis, and Targeted Crystallization Experiments in the Case of Diflunisal. <i>Crystal Growth and Design</i> , 2003, 3, 151-158.	1.4	76

#	ARTICLE	IF	CITATIONS
37	Polymorph Selection:â€™ Challenges for the Future?. Crystal Growth and Design, 2003, 3, 873-885.	1.4	206
38	Crystal Assembly:â€™ The Application of High Affinity Ligands and Habit Modification. Crystal Growth and Design, 2003, 3, 167-173.	1.4	4
39	A Novel Batch Cooling Crystallizer for in Situ Monitoring of Solution Crystallization Using Energy Dispersive X-ray Diffraction. Crystal Growth and Design, 2003, 3, 197-201.	1.4	22
40	Nucleation Control in Solution Mediated Polymorphic Phase Transformations:Â The Case of 2,6-Dihydroxybenzoic Acid. Journal of Physical Chemistry B, 2002, 106, 1954-1959.	1.2	102
41	Crystal engineering â€™ nucleation, the key step. CrystEngComm, 2002, 4, 257-264.	1.3	189
42	Crystal Polymorphism as a Probe for Molecular Self-Assembly during Nucleation from Solutions:â€™ The Case of 2,6-Dihydroxybenzoic Acid. Crystal Growth and Design, 2001, 1, 59-65.	1.4	141
43	Can crystal structure prediction be used as part of an integrated strategy for ensuring maximum diversity of isolated crystal forms? The case of 2-amino-4-nitrophenol. Physical Chemistry Chemical Physics, 2001, 3, 3819-3825.	1.3	33
44	Crystal engineering of polymorph appearance: the case of sulphathiazole. Powder Technology, 2001, 121, 46-52.	2.1	33
45	Stabilizing a solidâ€™solid interface with a molecular-scale adhesive. Nature, 1999, 402, 797-799.	13.7	31
46	Crystal Growth. , 1999, , 127-153.		2
47	Crystal chemistry and solvent effects in polymorphic systems Sulfathiazole. Journal of the Chemical Society, Faraday Transactions, 1998, 94, 1035-1044.	1.7	167
48	Disappearing polymorphs and the role of reaction by-products: the case of sulphathiazole. International Journal of Pharmaceutics, 1998, 172, 169-177.	2.6	103
49	Polymorphism in Molecular Crystals:â€™ Stabilization of a Metastable Form by Conformational Mimicry. Journal of the American Chemical Society, 1997, 119, 1767-1772.	6.6	321